Beyond current signals, trials designed for the hepatorenal question are still few; future studies should stage liver disease and pre-specify renal outcomes to test whether weight loss, SGLT2 inhibitors, GLP-1 RAs, statins, or other lipid-modulating agents change kidney trajectories in MASLD. This evidence concerns the gene GCG and liver disorder.